Vertex Pharmaceuticals and CRISPR Therapeutics announced that their gene editing therapy Casgevy has cured sickle cell disease in all 45 participants of a Phase 3 clinical trial.
Patients who previously suffered debilitating pain crises have been symptom-free for over 18 months.
